Transcode Therapeutics (RNAZ) Stock
Small cap biotech company focused on RNA science. Here's the price, business snapshot, and what's worth knowing about Transcode Therapeutics in October 2026.
Transcode Therapeutics Inc (ticker: RNAZ) is a very small-cap biotechnology company with a market capitalisation of approximately $12.63 million. The firm’s name indicates an orientation towards RNA science, but public investors should rely on the company’s filings and announcements for exact details on its programmes and milestones. As a microcap biotech, it is likely to be early-stage, with limited revenues, a small shareholder base and lower trading liquidity. Such stocks can be highly volatile and sensitive to binary events (e.g., study updates, regulatory news or financing rounds). Investors should weigh potential upside against common sector risks: heavy R&D spending, frequent need for external capital, dilution risk and uncertain clinical or commercial outcomes. This summary is general educational information only and not personal advice; values can rise or fall and past performance does not guarantee future returns. Check official filings, analyst notes and consider whether a microcap biotech fits your risk tolerance and portfolio timeframe.
Transcode Therapeutics (RNAZ) Stock Forecast
Analyst price target, next 12 months
$20.00
+1173.9% vs today's $1.57
Price range over the last 12 months
Close to its 12-month low
Analysts covering Transcode Therapeutics have a consensus 12-month target of $20.00, above the current price of $1.57.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 17 Jul 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Transcode Therapeutics' stock with a target price of $20, indicating strong growth potential.
Financial Health
Transcode Therapeutics is showing a solid financial position with good cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Microcap dynamics
Small market cap and low liquidity can amplify price moves; that may create opportunity but also increases risk and potential difficulty exiting positions.
Early-stage focus
If the company is development-led, progress hinges on scientific milestones and funding; successful results can re-rate a stock, while setbacks can be costly.
Do your homework
Review filings, management commentary and funding needs carefully — and remember that returns are not guaranteed and values can fall as well as rise.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
